{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Valvular+Disease&page=3", "query": { "condition": "Valvular Disease", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 93, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Valvular+Disease&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Valvular+Disease&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T07:30:07.194Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02164864", "title": "Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Percutaneous Coronary Intervention" ], "interventions": [ { "name": "Dabigatran Etexilate 110mg", "type": "DRUG" }, { "name": "Warfarin 3mg", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" }, { "name": "Dabigatran Etexilate 150mg", "type": "DRUG" }, { "name": "Clopidogrel or Ticagrelor", "type": "DRUG" }, { "name": "Warfarin 5mg", "type": "DRUG" }, { "name": "Warfarin 1mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2725, "start_date": "2014-07-22", "completion_date": "2017-06-05", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Cottonwood, Arizona • Mesa, Arizona + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cottonwood", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02164864" }, { "nct_id": "NCT03366649", "title": "Improving Mitral Repair for Functional Mitral Regurgitation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiomyopathy", "Cardiovascular Diseases", "Congestive Heart Failure", "Coronary Artery Disease", "Heart Disease", "Valvular Heart Disease", "Mitral Valve Disease" ], "interventions": [ { "name": "Undersizing Mitral Annuloplasty", "type": "PROCEDURE" }, { "name": "Papillary Muscle Approximation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2018-03-20", "completion_date": "2023-12-31", "has_results": true, "last_update_posted_date": "2025-01-16", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 3, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03366649" }, { "nct_id": "NCT06168942", "title": "A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Non-valvular Atrial Fibrillation", "Stroke", "Systemic Embolism" ], "interventions": [ { "name": "Experimental: Laminar Left Atrial Appendage Closure System", "type": "DEVICE" }, { "name": "Active Comparator: WATCHMAN / Amulet", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Biosense Webster, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2024-02-19", "completion_date": "2032-02-29", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06168942" }, { "nct_id": "NCT03242278", "title": "Real-world Dosing Patterns of Rivaroxaban in the United States", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Rivaroxaban (Xarelto, BAY59-7939)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12507, "start_date": "2016-02-12", "completion_date": "2016-03-01", "has_results": false, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03242278" }, { "nct_id": "NCT02100228", "title": "Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Apixaban", "type": "DRUG" }, { "name": "Parenteral heparin and/or oral Vitamin K antagonist", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1500, "start_date": "2014-07-14", "completion_date": "2017-02-08", "has_results": true, "last_update_posted_date": "2018-05-23", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 63, "location_summary": "Birmingham, Alabama • Avondale, Arizona • Chula Vista, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Avondale", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02100228" }, { "nct_id": "NCT03719144", "title": "Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 581, "start_date": "2019-04-08", "completion_date": "2020-03-24", "has_results": false, "last_update_posted_date": "2023-09-05", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03719144" }, { "nct_id": "NCT04281823", "title": "DeBakey Cardiovascular Magnetic Resonance Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiovascular Diseases" ], "interventions": [ { "name": "Cardiovascular Magnetic Resonance", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Dipan Shah", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100000, "start_date": "2008-04-01", "completion_date": "2058-04-01", "has_results": false, "last_update_posted_date": "2026-04-20", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04281823" }, { "nct_id": "NCT02561897", "title": "EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Electrophysiology Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2015-12", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2020-06-30", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 1, "location_summary": "Warren Township, New Jersey", "locations": [ { "city": "Warren Township", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02561897" }, { "nct_id": "NCT06763549", "title": "COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cardiopulmonary Failure", "Myocardial Infarction (MI)", "Heart Decompensation", "Heart Failure", "HFrEF - Heart Failure with Reduced Ejection Fraction", "HFpEF - Heart Failure with Preserved Ejection Fraction", "Syncopation", "Syncope", "Ischemic Cardiovascular Disease", "STEMI", "STEMI (ST Elevation MI)", "Atrial Fibrillation (AF)", "Atrial Enlargement", "LVF", "Conduction Defect", "Conduction Abnormalities", "Heart Block", "Valvular Diseases", "Cardiac Output, Low", "Stroke Volume", "Stroke Volume Variation", "Hyperkalemia", "Hypercalcemia", "Hypocalcemia", "LV Dysfunction", "QT Prolongation", "Sudden Cardiac Death Due to Cardiac Arrhythmia", "Ventricular Arrhythmia", "Pacing", "Pacing Induced Dyssynchrony", "Silent Ischemia", "Pericarditis", "Sleep Related Breathing Disorder", "RSA", "Apnea, Obstructive", "Cardiac Output Measurement", "Respiratory Impedance", "CRT And/or ICD", "Infarction", "Cardiomyopathies, Primary", "Hypertrophy" ], "interventions": [ { "name": "SUBPROTOCOL A", "type": "DEVICE" }, { "name": "SUBPROTOCOL B", "type": "DEVICE" }, { "name": "SUBPROTOCOL C", "type": "DEVICE" }, { "name": "SUBPROTOCOL D", "type": "DEVICE" }, { "name": "SUBPROTOCOL E", "type": "DEVICE" }, { "name": "SUBPROTOCOL F", "type": "DEVICE" }, { "name": "SUBPROTOCOL G", "type": "DEVICE" }, { "name": "SUBPROTOCOL H", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Peerbridge Health, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15000, "start_date": "2024-11-16", "completion_date": "2026-04-15", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 1, "location_summary": "Melbourne, Florida", "locations": [ { "city": "Melbourne", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06763549" }, { "nct_id": "NCT02043808", "title": "The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Atrial Fibrillation" ], "interventions": [], "intervention_types": [], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25586, "start_date": "2014-01", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-07-03", "last_synced_at": "2026-10-19T07:30:07.194Z", "location_count": 1, "location_summary": "Lexington, Massachusetts", "locations": [ { "city": "Lexington", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043808" } ] }